Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 3/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58396 | 1.00 | MMP13 (0.40) | MMP13CYP2C19HIF1AKDM4EPOLB | |
| SCHEMBL5981030 | 1.00 | MMP13 (0.40) | MMP13CYP2C19HIF1AKDM4EPOLB | |
| SCHEMBL5979942 | 0.90 | KMT2A (0.41) | MMP13CYP2C19HIF1AKDM4EPOLB | |
| SCHEMBL20732299 | 0.88 | ESR1 (0.36) | MMP13KMT2AMEN1RAB9ANPSR1 | |
| SCHEMBL22069882 | 0.88 | ESR1 (0.36) | MMP13KMT2AMEN1RAB9ANPSR1 | |
| SCHEMBL21086705 | 0.87 | MMP13 (0.38) | MMP13CYP2C19HIF1AKDM4EPOLB | |
| SCHEMBL20723962 | 0.87 | AAK1 (0.35) | MMP13KMT2AMEN1RAB9ANPSR1 | |
| SCHEMBL16176598 | 0.87 | AAK1 (0.40) | MMP13CYP2C19CYP2D6KMT2AMEN1 | |
| SCHEMBL88675 | 0.87 | MMP13 (0.40) | MMP13CYP2C19HIF1AKMT2AMEN1 | |
| SCHEMBL16176596 | 0.87 | AAK1 (0.40) | MMP13CYP2C19CYP2D6KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539682-A2 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF TUBULIN INHIBITORS | Wyeth Holdings Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004026814-A2 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF TUBULIN INHIBITORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | claimed |
| US-20040063904-A1 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | claimed |
| CN-118084733-B | Preparation method of key intermediate for synthesizing tubulin inhibitor | 重庆皓元生物制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12152083-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. | 2024-11-26 | — | — | US | disclosed |
| CN-118084733-A | Preparation method of key intermediate for synthesizing tubulin inhibitor | 重庆皓元生物制药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230317700-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-10-05 | — | — | US | disclosed |
| US-11591405-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. | 2023-02-28 | — | — | US | disclosed |
| EP-4029873-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | Zymeworks Inc. (CA) | 2022-07-20 | — | — | EP | disclosed |
| EP-3194421-B1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS INC (CA) | 2021-11-03 | — | — | EP | disclosed |
| CN-113416229-A | Cytotoxic and antimitotic compounds, and methods of use thereof | 酵活有限公司 | 2021-09-21 | — | — | CN | disclosed |
| WO-2016041082-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CDRD Ventures, Inc. (CA) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075735-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2016-03-17 | — | — | US | disclosed |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-7078572-B2 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | WYETH HOLDINGS CORPORATION (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050288486-A1 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | WYETH HOLDINGS CORPORATION (US) | 2005-12-29 | — | — | US | disclosed |
| US-6951955-B2 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | WYETH HOLDINGS CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1539682-A2 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF TUBULIN INHIBITORS | Wyeth Holdings Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004026814-A2 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF TUBULIN INHIBITORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20040063904-A1 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075735-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | MMP13 3545/4885CYP2C19 4458/4885HIF1A 4754/4885 |
| US-11591405-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | MMP13 3545/4885CYP2C19 4458/4885HIF1A 4754/4885 |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | MMP13 4582/4885CYP2C19 381/4885HIF1A 366/4885 |
| US-12152083-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | MMP13 3545/4885CYP2C19 4458/4885HIF1A 4754/4885 |
| US-20040063904-A1 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | TUBB1, TUBA1C, TUBB | MMP13 4387/4885CYP2C19 2431/4885HIF1A 3496/4885 |
| US-20050288486-A1 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | TUBB1, TUBB, TUBA1C | MMP13 4587/4885CYP2C19 1855/4885HIF1A 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.